Controversies in sepsis clinical trials: proceedings of a meeting of the International Sepsis Forum, Lausanne, Switzerland, September 29, 2001.

[1]  John C. Marshall,et al.  THE EFFECTS OF GRANULOCYTE COLONY-STIMULATING FACTOR IN PRECLINICAL MODELS OF INFECTION AND ACUTE INFLAMMATION , 2005, Shock.

[2]  Steven B. Johnson,et al.  Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels* , 2004, Critical care medicine.

[3]  C. Esmon,et al.  Why do animal models (sometimes) fail to mimic human sepsis? , 2004, Critical care medicine.

[4]  G. Bernard,et al.  Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial* , 2003, Critical care medicine.

[5]  J. Vincent,et al.  Serial evaluation of the SOFA score to predict outcome in critically ill patients. , 2001, JAMA.

[6]  A. González-Quintela,et al.  Cecal Ligation and Puncture as a Model of Sepsis in the Rat: Influence of the Puncture Size on Mortality, Bacteremia, Endotoxemia and Tumor Necrosis Factor Alpha Levels , 2001, European Surgical Research.

[7]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[8]  D. Schoenfeld,et al.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.

[9]  J. Kress,et al.  Outcomes of critically ill cancer patients in a university hospital setting. , 1999, American journal of respiratory and critical care medicine.

[10]  G. Wells,et al.  A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. , 1999, The New England journal of medicine.

[11]  C. Sprung,et al.  Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. , 1998, Critical care medicine.

[12]  P. Peduzzi,et al.  Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. , 1997, JAMA.

[13]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[14]  C. Sprung,et al.  Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. , 1995, Critical care medicine.

[15]  L. Moldawer,et al.  BLOCKADE OF TUMOR NECROSIS FACTOR REDUCES LIPOPOLYSACCHARIDE LETHALITY, BUT NOT THE LETHALITY OF CECAL LIGATION AND PUNCTURE , 1995, Shock.

[16]  L. Hinshaw,et al.  Preclinical review of anti‐tumor necrosis factor monoclonal antibodies , 1993, Critical care medicine.

[17]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.

[18]  E. Abraham,et al.  Immunological therapy of sepsis: experimental therapies , 2001, Intensive Care Medicine.